Our mission is to offer sustainable, non-toxic medical engineering treatment combined with long term immunotherapy with reduced side effects, compared to systemic chemotherapy drugs and radiation therapy.

Go-AI believes early detection of cancer to deliver transformative progress in cancer survival and wider skill sets beyond cancer biology are essential, including engineers, chemists, physicists, technology developers, and behavioural and computer scientists. Integrated, interdisciplinary collaboration is key to bringing new ideas to address the challenges of early cancer detection. We believe that early detection of cancer is approaching a tipping point, as biological insight and technological capacity are increasing at an unprecedented rate and as public and private funders of research are increasingly willing to invest. (Source: Early detection of cancer | Science)

Together with Dr Balaji (Baloo) Panchapakesan, Go-AI has established an equal 50/50 partnership Nanotherapy Plus Pty Ltd.

We will implement a Test to Treat Strategy “Nanobomb Plus” to provide a comprehensive solution of early detection via a new patent pending Liquid Biopsy Tracker diagnostic tool + nanotechnology “Nanobomb” therapy + immunotherapy Checkpoint Inhibitors.

The objective of ‘Nanobomb Plus’ is to improve treatment efficacy/ survival outcome through early detection, followed by primary non-toxic therapy Nanobomb, and secondary immunotherapy to eliminate cancel cells by activating the T-cells to prevent tumour regrowth and to provide ongoing prophylaxis supported by T-cell memory.